Enzastaurin Explained

Enzastaurin is a synthetic bisindolylmaleimide with potential antineoplastic activity. Binding to the ATP-binding site, enzastaurin selectively inhibits protein kinase C beta, an enzyme involved in the induction of vascular endothelial growth factor (VEGF)-stimulated neo-angiogenesis. This agent may decrease tumor blood supply, preventing growth.

Trials

In 2013 it failed a phase III clinical trial for lymphoma.^[1]

In 2022, there is an upcoming initial trial called PREVEnt to look into the effectiveness of Enzastaurin for the treatment of Vascular Elhers-Danlos syndrome (vEDS). ^{[2] [3] [4]}

External links

• Enzastaurin hydrochloride, National Institutes of Health

Notes and References

1. http://www.genengnews.com/gen-news-highlights/lilly-halts-development-of-lymphoma-drug-after-phase-iii-failure/81248350/ Lilly Halts Development of Lymphoma Drug After Phase III Failure
2. Web site: New vEDS clinical trial. 2022-01-19. PREVEnt Trial. en-US.
3. Web site: Aytu BioPharma Adds Late-Stage Pediatric Onset Rare Disease Asset to Development Pipeline from Rumpus Therapeutics. 2022-01-19. BioSpace. en-US.
4. Web site: Clinical Trials. 2022-01-19. FIGHT vEDS 3.0. en.